Home > Blog > Travel & Hospital Navigation Key Takeaways “Basic,” “standard,” “VIP,” and “executive” are hospital-defined package labels, not universal medical standards. A practical comparison starts with baseline screening, then considers age, personal and family history, previous results, and screening goals. New, persistent, or concerning symptoms require an appropriate clinical assessment rather than a larger preventive screening package. Broader testing may produce more

Home > Blog > Travel & Hospital Navigation By MedBridgeNZ | Evidence last checked: August 2026 Key Takeaways Investigational Status: CD7-directed therapies for T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) are not commercially approved medications in China. They remain investigational under hospital-sponsored or clinical trial protocols. Overcoming Biological Hurdles: Investigational platforms have explored natural selection, intracellu

Home > Blog > Travel & Hospital Navigation By MedBridgeNZ | Last updated: August 2026 Key Takeaways Conditional BCMA Approvals: China’s National Medical Products Administration (NMPA) has conditionally approved several autologous BCMA-directed CAR-T products for specified adults with relapsed or refractory multiple myeloma after prior treatment. Alternative Antigen Targeting: For patients experiencing disease progression after BCMA-targeted therapy, investigational GPRC5D CAR

Home > Blog > Travel & Hospital Navigation Key Takeaways Mechanisms of Failure: Relapse following cellular immunotherapy typically occurs through either antigen-negative escape (loss or mutation of the targeted protein) or antigen-positive persistence failure (T-cell exhaustion or early clearance). Target Re-Profiling Is Essential: Establishing next-step feasibility requires a repeat biopsy with quantitative flow cytometry or immunohistochemistry to confirm whether the origin

Home > Blog > Travel & Hospital Navigation Key Takeaways Initial remote acceptance for CAR-T therapy is based on historical medical records and does not constitute final approval for apheresis. Institutional protocols require continuous reassessment of disease progression, blood counts, and infection status prior to cell collection. Recent chemotherapy or bridging therapies often necessitate strict washout periods to ensure sufficient lymphocyte viability. The clinical feasib

Home > Blog > Travel & Hospital Navigation Key Takeaways China operates a dual-track healthcare system where high-volume clinical expertise is concentrated in public Grade 3A hospitals, while private/international hospitals focus on administrative accessibility and premium logistical support. The fundamental CAR-T products and cellular technologies remain consistent across hospital types; the primary differences lie in bilingual support, consultation formats, and payment work

Home > Blog > Travel & Hospital Navigation By MedBridgeNZ | Last updated: 12 August 2026 For international patients, the CAR-T treatment timeline in China is usually measured in weeks, not days. It may include medical-record review, travel, reassessment, leukapheresis, cell manufacturing, lymphodepletion, infusion, monitoring and clearance to return home. Manufacturing time is only one part of the journey. This guide explains the stages that can change the total stay—and what

Home > Blog > Travel & Hospital Navigation By MedBridgeNZ | Last updated: 11 August 2026 International patients researching commercial CAR-T vs clinical trials in China are often presented with two apparently simple choices: pay for a commercially available product or try to enter a clinical trial. The real distinction is more complex. An approved product is approved only for specified indications and still requires hospital assessment. A clinical trial offers access under a

Home > Blog > Travel & Hospital Navigation By MedBridgeNZ | Last updated: 10 August 2026 If you have recently received chemotherapy and are considering CAR-T, the CAR-T washout period cannot be reduced to one universal number. The relevant interval depends on the treatment, the disease, whether T cells have already been collected, the intended CAR-T product or protocol, blood-count recovery, infection status, organ function and the receiving centre's requirements. Evidence sc

Home > Blog > Travel & Hospital Navigation For international patients considering CAR-T pre-screening in China, one of the most useful steps can take place before any flight is booked: preparing a medical record package that allows the receiving specialist or hospital to understand the diagnosis, previous treatments, current disease status and treatment-specific questions. In this guide, “pre-screening” means preliminary review by the receiving medical institution or speciali

Home > Blog > Travel & Hospital Navigation Receiving an overseas cancer second opinion is not the end of the decision-making process. For many patients, the more important question comes next: How should the overseas specialist’s opinion be discussed with the doctors who already know the patient, have access to current tests, and remain responsible for ongoing care? A medical tourism China second opinion may confirm the existing treatment plan, raise another possibility, iden

Home > Blog > Travel & Hospital Navigation A medical concierge for cancer patients should not be assessed solely by whether a patient books a flight, attends a Chinese hospital or proceeds with treatment overseas. For some patients, the most useful coordination outcome is confirmation that an in-person consultation in China has a defined purpose. For others, it may be a remote specialist opinion, clarification of an institutional limitation, continued care under the local med

Home > Blog > Travel & Hospital Navigation International patients planning treatment in China may ask the receiving hospital for an official invitation letter before arranging their visa and travel. However, a Chinese hospital medical invitation letter is not automatically available from every hospital, clinical department or specialist. A doctor may agree to review a patient’s records or arrange an outpatient consultation while the hospital has no administrative pathway for

Home > Blog > Travel & Hospital Navigation A China hospital treatment cost estimate can help an international patient prepare an initial budget. However, the figure should not automatically be interpreted as the total amount payable from the first consultation through completion of treatment. An estimate may relate only to a medication regimen, one treatment cycle, a planned procedure or an assumed period of hospitalization. It may not include additional tests, treatment-rela

Home > Blog > Travel & Hospital Navigation To prepare medical records for a China specialist review, patients need more than a folder containing every available hospital document. A specialist-ready record package should clearly show: the documented diagnosis; the treatment already received; how the condition has changed; the patient’s current medical situation; and the questions the specialist is being asked to address. A folder may contain hundreds of pages and still be dif

Home > Blog > Travel & Hospital Navigation A Chinese hospital may agree to review a cancer case, but this does not establish that the patient is medically stable enough to complete an international journey. Before flying to China for cancer treatment, three separate questions may need to be addressed: Is the patient medically stable enough for long-haul travel? Will the airline accept the passenger and any required medical equipment? Has the receiving hospital confirmed a rel

Home > Blog > Travel & Hospital Navigation Guangzhou Medical Tourism at a Glance Guangzhou offers two broad pathways for international patients: separately administered international or premium services within some public Class 3A hospitals, and private international hospitals with their own clinical and administrative systems. International patients can use administrative pathways to submit relevant medical records, with translation arranged where required by the receiving

Home > Blog > Travel & Hospital Navigation West China Hospital is a high-volume tertiary referral hospital in Chengdu, China, with specialized departments that may be relevant to selected international patients [1]. Access is not automatic: the receiving department must independently review the patient’s medical records, determine whether further consultation or assessment is appropriate, confirm current capacity, and provide case-specific next-step information. MedBridgeNZ p

Home > Blog > Travel & Hospital Navigation Quick Answer For international patients exploring cross-border healthcare, accessing tertiary institutions in Beijing involves navigating specific administrative and clinical requirements. Core pathways typically include: Formatting and preparing medical records to meet the specific submission standards of the receiving Chinese institution. Identifying potentially relevant hospitals, departments, or specialists based on the clinica

Home > Blog > Travel & Hospital Navigation International patients may consider medical care in Shanghai for different reasons. Some face long waits for specialist assessment or surgery at home. Others are seeking a second opinion, a treatment pathway that is not routinely available in their country, or an alternative self-pay option for complex care. Shanghai has a large network of public Grade 3A hospitals, specialist medical centers and private hospitals serving internation